Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E coli vaccine 3
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
E coli vaccine 3 is an investigational vaccine candidate developed by Pfizer to prevent infections caused by pathogenic strains of Escherichia coli. It is one of several candidates (including E coli vaccines 1, 2, 4, and 5) being evaluated in a Phase 1 clinical trial (NCT07122986) to assess safety, tolerability, and immunogenicity in healthy adults aged 18-64. The vaccine is composed of killed or partial bacterial components that are non-infectious and is administered via intramuscular injection on a two-dose schedule at 0 and 6 months.
- Other names
- escherichia coli vaccine 3
Beyond the preview
Go deeper on E coli vaccine 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E coli vaccine 3.